In plain English
Peptide molecules sometimes stick to each other. When enough of them clump together, scientists call it aggregation [1].
Clumps come in two broad kinds. Some are messy, with no regular pattern (amorphous). Others are neat, long fibres called amyloid-like fibrils, where the chains line up in flat sheets (β-sheets) [1, 3].
Many things push peptides to clump. These include the order of amino acids, how concentrated the solution is, its acidity (pH), contact with air or container surfaces, shaking, freezing and impurities [1]. Some clumps break apart again. Others are effectively permanent [1].
Clumps can range from a few molecules to particles visible by eye. No single lab test sees every size, so labs use several tests together [2, 4].
The short version
- Aggregation means peptide molecules sticking together [1].
- Aggregates can be amorphous or fibrillar [1].
- Detection needs more than one method [2].
What is peptide aggregation?
Aggregation is a physical stability problem. A peptide can be chemically intact, with every bond in place, and still self-associate into larger species. A 2017 review of peptide therapeutics describes many cases where self-association, into either amorphous aggregates or highly structured fibrillar species, limits a peptide’s use [1].
Key features from that review [1]:
- Two broad structural types. Aggregates can be amorphous or highly structured, such as amyloid-like fibrils.
- Reversible or not. In some cases aggregation is reversible; in others it is effectively irreversible.
- In solution or on surfaces. Aggregates can form in solution, or on surfaces after the peptide adsorbs to them.
Aggregates also cover an enormous size range. A review of protein aggregate analysis describes particles from a few nanometres up to visible particles larger than about 50 µm [2].
Why peptides are prone to aggregation
Many short peptides lack a stable folded structure in solution. Glucagon, a 29-amino-acid hormone, equilibrates between unordered and α-helical states, and can transform into a different, β-sheet-rich amyloid-like structure under various conditions [5]. See Peptide Bonds and Peptide Structure Explained.
Several well-known peptides form fibrils in laboratory conditions. Examples reported in the literature include glucagon (29 residues) at pH 2 and at pH 8.5–9.7, salmon calcitonin (32 residues) at neutral pH, GLP-1, and insulin (51 residues) at pH 2 [1].
Amyloid-like fibrils: the ordered form
Amyloid-like fibrils share a common core architecture, called the cross-β spine. In a landmark 2005 study, researchers solved the atomic structure of this spine using a seven-residue peptide segment that forms amyloid-like fibrils and closely related microcrystals [3]. They found:
- a double β-sheet, with each sheet formed from parallel peptide segments lined up in register
- side chains from the two sheets interlocking into a dry, tightly self-complementing “steric zipper”
- each segment hydrogen-bonded to its neighbours through both backbone and side-chain hydrogen bonds.
The authors noted that this structure helps explain why fibrils are so stable, why they can self-seed (pre-formed fibrils promote new fibril growth), and why they tend to form several different structural variants (polymorphs) [3]. The 2017 review adds that fibrils are stabilised by the hydrophobic effect, van der Waals interactions, π–π interactions between aromatic rings, and hydrogen bonds [1].
How fibrils form: lag, growth and plateau
Fibril formation often follows nucleation-dependent kinetics. Measured over time, it shows three phases [1]:
- Lag phase. Oligomers, including nucleating species, and short fibrils form, but little bulk change is visible.
- Growth (elongation) phase. Once enough nuclei exist, fibrils grow rapidly.
- Plateau. Growth levels off.
Two practical consequences follow:
- Concentration matters. For peptides that follow this pathway, increasing peptide concentration shortens both the lag time and the time to half-completion [1].
- Seeding matters. Glucagon can form several types of fibril, each through a distinct nucleation-dependent pathway influenced by solution conditions, and each can be self-propagated by seeding [6]. A small number of pre-existing fibrils can therefore speed up aggregation in a fresh solution.
What drives aggregation?
The 2017 review groups the influences into intrinsic and external factors [1].
| Factor | What the review reports |
|---|---|
| Amino acid sequence | A sequence’s intrinsic tendency to aggregate is now well understood, and prediction programs are available. Hydrophobicity, charge state and β-sheet-forming tendency all contribute [1] |
| Concentration | Higher concentration shortens lag time for fibril-forming peptides [1] |
| pH and net charge | Electrostatic interactions play major roles. Near the isoelectric point (where net charge is close to zero), amorphous aggregates have been observed instead of fibrils [1] |
| Surfaces and interfaces | Air–water and ice–water interfaces behave as hydrophobic interfaces. Insulin has been reported to aggregate at air–water interfaces [1] |
| Chemical degradation and modification | Chemical changes often alter hydrophobicity and secondary structure, and so change aggregation behaviour [1] |
| Impurities | Residual synthesis reagents and counter-ions, such as trifluoroacetic acid (TFA), acetate and hydrochloride salts, are listed among impurities that can matter [1] |
| Temperature, pressure, agitation and freeze-drying | Each can affect aggregation, in many cases in ways that are difficult to predict [1] |
For related topics, see Peptide Storage and Stability, Predicting Peptide Solubility, Counter-Ions in Peptides: TFA vs Acetate and Freeze-Drying Explained.
How laboratories detect aggregation
No single technique covers the whole size range of aggregates, so a combination of methods is needed [2]. Analysts also use orthogonal methods, meaning independent techniques based on different physical principles, to cross-check one another [2].
| Method | What it measures | Notes |
|---|---|---|
| Visual inspection | Clarity, opalescence, turbidity and visible particles | Detects particles larger than about 50 µm [2] |
| Size-exclusion chromatography (SEC) | Separates monomer from oligomers by size | Uses small columns; a few to tens of µg of sample can give a result [2] |
| Dynamic light scattering (DLS) | Size distribution of particles in solution | Covers roughly 1–2 nm up to 3–5 µm [2] |
| Analytical ultracentrifugation (AUC) | Sedimentation behaviour of molecules and aggregates | Often used in sedimentation velocity mode [2] |
| Nanoparticle tracking analysis | Size of individual particles via light scattering | About 20 nm to 1 µm [2] |
| Flow imaging microscopy | Count, size and shape of micron-sized particles | About 1–400 µm; can help tell protein particles from other particles [2] |
| Thioflavin T (ThT) fluorescence | Formation of fibrils with regular β-sheet structure | Usually used to follow fibril formation over time [1, 7] |
| Circular dichroism (CD) | Secondary-structure content | Can show a shift from helix or random coil towards β-sheet [5, 8] |
Thioflavin T
Thioflavin T is a fluorescent dye first described in 1959. Its fluorescence increases greatly when it binds amyloid fibrils, which has made it one of the most widely used tools for identifying fibrils in vitro [7]. Aggregation kinetics are usually followed by the rise in ThT fluorescence as it binds fibrils containing regular β-sheet structure [1]. Because the dye responds to that ordered structure, it is a test for fibrils rather than a general test for every kind of aggregate.
Measurement can change the sample
Aggregation is hard to measure partly because the measurement itself can create or destroy aggregates. One analyst reported an “aggregate” peak in SEC that turned out to be a partially denatured monomer. Another system formed transient, very sticky oligomers that were hard to measure by SEC. Comparing against sedimentation velocity (AUC) helped develop a better SEC method [4]. The same review notes that only smaller aggregate species are generally reversible, and that aggregates have a broad range of lifetimes [4].
Why aggregation matters for research material
Aggregation changes what is actually present in a sample. Material that has partly aggregated contains less free, monomeric peptide than its weight suggests, and the aggregated fraction may behave differently in an experiment. For biotech product development, reviewers recommend building aggregate analysis into characterisation, with methods chosen to suit each product [2].
A purity figure on a Certificate of Analysis usually comes from a separating method such as HPLC. Given how many techniques aggregate analysis can require, a single purity figure may not describe the full aggregation state of a material [2, 4]. See How to Read a Peptide COA and Common Peptide Impurities.
What this means in Australia
Quality is unverified for unapproved products. The TGA states that unapproved peptide products have not been evaluated for safety, quality or effectiveness. It notes that important information remains unknown, including how they are manufactured, whether they are sterile and what substances they actually contain, and that labelling may be inaccurate or misleading [9].
Quality data do not change legal status. Good analytical data, including aggregation testing, describe a batch. They do not place a product on the Australian Register of Therapeutic Goods (ARTG) or change its Poisons Standard status. Several peptides, such as BPC-157 and TB-500, are named in Schedule 4 and Appendix D, clause 5 of the current Poisons Standard (October 2026) [10]. Schedule 4 means prescription-only. Appendix D, clause 5 means possessing the substance without authority is illegal.
“Research use only” labels. The TGA has stated that a “research use only” disclaimer does not make supply lawful, and does not change a product’s regulatory status, permit importation, or remove advertising or supply obligations [9].
This is general information, not legal advice. Laws change; check the current Poisons Standard and TGA guidance.
Frequently asked questions
What is peptide aggregation?
It is the self-association of peptide molecules into larger species, either amorphous aggregates or ordered amyloid-like fibrils [1].
Why do peptides aggregate?
Sequence, concentration, pH and net charge, surfaces and interfaces, impurities, temperature, agitation and freeze-drying all influence aggregation [1].
Is peptide aggregation reversible?
Sometimes. Some aggregation is reversible, while some is effectively irreversible. Generally, only smaller aggregate species are reversible [1, 4].
What is a thioflavin T assay?
A fluorescence test in which the dye thioflavin T brightens on binding amyloid-like fibrils. It is widely used to follow fibril formation over time [1, 7].
Can one test detect all aggregates?
No. Aggregates range from nanometres to visible particles, and no single method covers that range, so laboratories combine several techniques [2, 4].
References
- Zapadka KL, Becher FJ, Gomes dos Santos AL, Jackson SE. Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus. 2017;7(6):20170030. doi:10.1098/rsfs.2017.0030. PMID: 29147559
- den Engelsman J, Garidel P, Smulders R, et al. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res. 2011;28(4):920–933. doi:10.1007/s11095-010-0297-1. PMID: 20972611
- Nelson R, Sawaya MR, Balbirnie M, et al. Structure of the cross-beta spine of amyloid-like fibrils. Nature. 2005;435(7043):773–778. doi:10.1038/nature03680. PMID: 15944695
- Philo JS. Is any measurement method optimal for all aggregate sizes and types? AAPS J. 2006;8(3):E564–E571. doi:10.1208/aapsj080365. PMID: 17025274
- Bao Z, Cheng YC, Wei JJ, Luo MZ, Zhang JY. Secondary structure characterization of glucagon products by circular dichroism and nuclear magnetic resonance spectroscopy. Molecules. 2022;27(22):7805. doi:10.3390/molecules27227805. PMID: 36431905
- Pedersen JS. The nature of amyloid-like glucagon fibrils. J Diabetes Sci Technol. 2010;4(6):1357–1367. doi:10.1177/193229681000400609. PMID: 21129330
- Biancalana M, Koide S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta. 2010;1804(7):1405–1412. doi:10.1016/j.bbapap.2010.04.001. PMID: 20399286
- Kuril AK, Vashi A, Subbappa PK. A comprehensive guide for secondary structure and tertiary structure determination in peptides and proteins by circular dichroism spectrometer. J Pept Sci. 2025;31(1):e3648. doi:10.1002/psc.3648. PMID: 39135381
- Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety advisory, 13 April 2026. tga.gov.au. Accessed 11 October 2026.
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327). Federal Register of Legislation. legislation.gov.au/F2026L01327/latest/text. Accessed 11 October 2026.
Important information and disclaimer
General information only. This article is published for general educational and informational purposes. It summarises published scientific literature and public regulatory information as at the “last reviewed” date shown above. It is not medical, health, pharmaceutical, veterinary or legal advice, and it must not be relied on as a substitute for advice from a qualified professional about your circumstances.
Not for human or animal use. Nothing in this article recommends, endorses or describes the use of any substance in humans or animals. Findings from cell, animal or early human studies cannot be assumed to apply to people. The compounds discussed have not been evaluated by the Therapeutic Goods Administration (TGA) for safety, quality or efficacy unless the article expressly states otherwise. Any research materials offered by Iconic Peptides are supplied solely for in vitro and laboratory research.
No therapeutic claims. Iconic Peptides makes no claim that any product treats, cures, prevents, alleviates or diagnoses any disease, condition or symptom. References to published studies, clinical trials or medicines approved by regulators are factual descriptions of the scientific and regulatory record. They are not representations about any product we supply.
Regulatory status. Many peptides are scheduled substances under the Poisons Standard. Some are prescription-only (Schedule 4), and some may not be possessed without authority (Appendix D). The TGA has stated that a “research use only” label does not make supply lawful, change a product’s regulatory status, or remove advertising or supply obligations. State and territory laws may also apply. You are responsible for knowing and complying with all laws that apply to you. Regulatory information in this article may change after the review date.
Accuracy and third-party sources. We take care to cite and verify every source, but we do not warrant that this article is complete, current or error-free. Citing a study or organisation does not mean that its authors or that organisation endorse Iconic Peptides.
Limitation of liability. To the maximum extent permitted by law, Iconic Peptides, its owners, employees and contributors exclude all liability for any loss, damage, injury or expense, whether direct, indirect or consequential, arising from use of or reliance on this article or any misuse of any product. Nothing in this disclaimer excludes, restricts or modifies any right or remedy under the Australian Consumer Law that cannot lawfully be excluded.
Age restriction. This website is intended for adults aged 18 and over.
